Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2963016 vs Lantus in Type 2 Diabetes on OAMs (China Phase 3)
CTR20171055Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Mar 2018; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20171055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171055.